A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 155
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MVAC
Long Form : methotrexate, vinblastine, doxorubicin, and cisplatin
No. Year Title Co-occurring Abbreviation
2020 Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. CSS, GC, GCb, OS, PC, RFS, RNU, UTUC
2020 Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. DUH, GC, MIBC, pCR
2020 Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. COXEN, GC, GEMs
2019 Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. CI, GC, OR, SEER, VTE
2019 Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis. AMUC, CI, GC, GP, HR, OR, ORR, OS, PFS, PGC, RCTs
2019 [Systemic treatment of metastatic tumors of the upper urinary tract]. UTUC
2018 Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials. CrI, GC, HRs, ORR, ORs, OS, PCG, PFS, RCTs, SUCRA, TTP, UC
2018 Gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis. DFS, DSS, GC, MIBC, OS
2018 Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. GC, MIBC, NAC, pCR, pPR, RC
10  2018 Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. GC, MIBC, NAC, OS, pT0
11  2018 Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. ---
12  2018 PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. CPI, EMA, FDA, mUC
13  2017 Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. AC, ART, HRs, LN, OS, RC
14  2017 Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study. ---
15  2017 Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer. GC, OS, pCR, PFS
16  2017 Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population. CSS, Gem-Carbo, Gem-Cis, OS
17  2017 The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. BSC, CI, GC, HR, OS
18  2016 A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. DD, GEP, OS, TUR, UC
19  2016 Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. GC, NAC, RC
20  2016 Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). GC, OS, UC
21  2016 Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. CI, GC, HR, MIBC, NCT, OS
22  2016 Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. NACT, pCR, VH
23  2016 Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis. CI, GC, PRISMA
24  2016 Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? CI, NAC
25  2016 Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder. CIs, GC, HR, mUCB
26  2015 Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. cT2, GC, pCR
27  2015 Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. BCa, GC, NAC, RC
28  2015 Perioperative chemotherapy for muscle invasive bladder cancer. MIBC, NAC
29  2015 Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP). CI, GP, HR, OS, PFS, UC
30  2015 Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. CI, ev, HR, LVI, OS, RC, TTR, UCB
31  2015 The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. HR, OS, PFS, UCB, UTUC
32  2015 The role of genomics in the management of advanced bladder cancer. ABC, FDA
33  2015 [Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy]. ---
34  2015 [Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?]. ---
35  2014 Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. BC, CRT, OS, PFS, RC
36  2014 Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. CI, CSS, HR, TTAC
37  2014 Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. CI, CSS, HR, TTAC
38  2014 Induction chemotherapy followed by surgery in node positive bladder cancer. CSS, NPBC
39  2014 Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. CR, CT, FDG-PET, MVA, OS, PET2, PFS, PR, SD, TCC, UVA
40  2014 Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment. CI, GC, UC
41  2014 Remarkable response to neoadjuvant therapy with methotrexate, vinblastine, adriamycin, and Cisplatin for undifferentiated bladder carcinoma: a case report and literature review. ---
42  2014 Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy. RMC
43  2014 Systemic therapy for bladder cancer - a medical oncologist's perspective. GC
44  2013 Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. GC, RFS
45  2013 Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. ---
46  2013 Malignant urothelial carcinoma of urinary bladder in a young child: a rare case report. ---
47  2013 Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. GC
48  2013 Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. OS
49  2013 Risk factors for refractory febrile neutropenia in urological chemotherapy. DE, FN
50  2013 The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). GC, MSI
51  2013 [A case of portal vein thrombosis during chemotherapy for bladder cancer]. GC
52  2013 [Clinical guidelines for diagnosing, treatment and monitoring patients with bladder cancer--Croatian Oncology Society and Croatian Urology Society, Croatian Medical Association]. BCG, GC
53  2013 [Effects of neoadjuvant chemotherapy on the prognostic mortality risk of invasive transitional bladder cancer: a meta-analysis]. MCV, RCTs
54  2013 [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer]. GC
55  2012 A fluorescence-based assay for monitoring clinical drug resistance. MDR
56  2012 Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. G-CSF, GP, OS, TTP
57  2012 Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. GC
58  2012 [The effect of presurgical gemcitabine cisplatin chemotherapy for urothelial carcinoma]. GC
59  2011 A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. IgG, PPV, UC
60  2011 Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. TCC, TURBT
61  2011 Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. GCD, ORR, OS, PFS, UC
62  2011 Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). UC
63  2011 First- and second-line therapy for metastatic urothelial carcinoma of the bladder. gc
64  2011 Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. CIHNAL, EMBASE, GCarbo, GCis, GCisPac, LILACS, MEDLINE, OS
65  2011 Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. GCarbo, GCis, GCisPac, MCarboV
66  2011 Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. ---
67  2011 The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. EBRT
68  2011 Two cases of plasmacytoid variant of urothelial carcinoma of urinary bladder: systemic chemotherapy might be of benefit. MRI
69  2011 [Chemotherapy for urological cancer : usefulness and feasibility of current protocols]. GC, UFT, VIP
70  2011 [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. GC, hENT1
71  2011 [The role of chemotherapy in the management of bladder cancer]. ---
72  2010 Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma. UC
73  2010 Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis. OS, PFS
74  2009 Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. GC
75  2009 Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. DBI, GGH
76  2009 Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. GC, NC, RC
77  2009 Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. ---
78  2009 Systemic therapy of advanced urothelial cancer. ---
79  2009 [Response to adjuvant chemotherapy after radical cystectomy in patients with infiltrative bladder: Analysis of 397 cases]. ---
80  2008 Primary choriocarcinoma of the urinary bladder. hCG-beta
81  2007 Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder. 5-HT3R, G-CSF
82  2007 Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. PS, TCC
83  2007 Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. UC
84  2007 Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. PFS
85  2006 Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. BPI, FACT-Cx, GOG, OS, PFS, QOL, TC
86  2006 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. CI, GC, TCC
87  2006 Perioperative chemotherapy for bladder cancer. CMV
88  2006 Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. ---
89  2006 Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. GC
90  2006 Systemic chemotherapy options for metastatic bladder cancer. ---
91  2006 [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)]. GC
92  2005 Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. CI, DIP, PR
93  2005 Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer. GC
94  2005 Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. GC, HR, TCC
95  2005 Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. PFS, QOL
96  2005 The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan. CR, MEC, PD, PR
97  2005 The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. CIMV, DC, PS
98  2005 The role of taxanes in the management of bladder cancer. ---
99  2005 [Inguinal lymph node metastasis of bladder carcinoma ten years after cystourethrectomy: a case report]. CT, SCC, TCC
100  2005 [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy]. HD, M-VAC